Drugs / PBCAR19B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04649112 | Jun 2021 → Dec 2022 | B-cell non-Hodgkin lymphoma | Precision BioSciences, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-05-31 | Precision BioSciences, Inc. | Results Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward precisionbiosciences.com ↗
PBCAR19B Stealth Cell Achieved 71% ORR with No Grade 3 or Greater Allogeneic CAR T Related Adverse Events; Most Compelling Signal in Third Line DLBCL (n=5) with 80% ORR and 60% CR (MRD-) |
| 2021-10-15 | Precision BioSciences, Inc. | Results Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells precisionbiosciences.com ↗
Across four clinical programs in more than 100 patients treated with PBCAR T cells, Precision BioSciences has seen no evidence of chromosomal abnormalities. |
| 2021-06-04 | Precision BioSciences, Inc. | Results Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma precisionbiosciences.com ↗
In preclinical studies, the anti-CD19 PBCAR19B stealth cell exhibited substantial resistance to rejection mediated by both allo-reactive T cell and NK cells, suggesting the potential utility of this approach. |
| 2021-01-19 | Precision BioSciences, Inc. | Regulatory Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma precisionbiosciences.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBCAR19B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04649112 ↗ |
| Modality | Cell therapy | “allogeneic anti-CD19 CAR T Cells” NCT04649112 ↗ |
| Route | Intravenous | “Route of Administration: Intravenous injection/infusion.” NCT04649112 ↗ |
| Target | CD19 | “anti-CD19 CAR T Cells” NCT04649112 ↗ |